The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 748.80 million in 2022 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart muscle disease caused by the buildup of abnormal deposits of amyloid protein in the heart. Treatment options target the underlying cause by modifying disease progression or alleviating symptoms to improve quality of life.
Market Dynamics:
The growth of the ATTR-CM treatment market is driven by the rising number of patients diagnosed with ATTR-CM and the approval of novel drugs for treatment. According to studies, diagnosis rates are increasing thanks to more widespread clinical awareness and the availability of non-invasive diagnostic tools. Additionally, several pharmaceutical companies are investing heavily in R&D to develop new precision medicines for ATTR-CM, with a few therapies recently receiving approval and many others in clinical trials. This expanding treatment landscape is set to propel market growth over the forecast period.
Market key trends:
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market has been witnessing a rise in research and development activities for innovative treatment options. ATTR-CM usually affects the heart and is caused due to a buildup of abnormal deposits of amyloid protein called transthyretin in the heart tissue. conventional treatments have limited efficacy in halting or reversing the progression of heart muscle damage. Hence, new drug candidates that can prevent the aggregation of misfolded transthyretin protein are being researched. Gene silencing therapies have emerged as a promising treatment approach and are in clinical trials.
SWOT Analysis
Strengths: robust pipeline of drug candidates in clinical trials, increasing awareness about ATTR-CM condition.
Weaknesses: high treatment costs, conventional drugs have limited efficacy.
Opportunities: demand for effective treatments, growth in geriatric population susceptible to ATTR-CM.
Threats: regulatory hurdles for approval of new drugs, pricing pressure on pharmaceutical companies.
Key Takeaways
The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing prevalence of heart conditions caused due to amyloid deposits and aging population.
North America currently dominates the ATTR-CM treatment market owing to presence of major pharmaceutical companies involved in research and approvals. The region is expected to retain its leading position during the forecast period.
Key players operating in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market incorporate Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
